{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T17:39:25Z","timestamp":1781804365513,"version":"3.54.5"},"reference-count":44,"publisher":"Elsevier BV","issue":"43","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["105-2314-B-002-055-MY2"],"award-info":[{"award-number":["105-2314-B-002-055-MY2"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.vaccine.2021.09.035","type":"journal-article","created":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T08:46:34Z","timestamp":1632213994000},"page":"6378-6384","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Safety surveillance of varicella vaccine using tree-temporal scan analysis"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2327-1295","authenticated-orcid":false,"given":"Chia-Hung","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4344-9567","authenticated-orcid":false,"given":"Wan-Ting","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chu","family":"Chie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Arnold Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.vaccine.2021.09.035_b0005","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1001\/jama.287.5.606","article-title":"Varicella disease after introduction of varicella vaccine in the United States, 1995\u20132000","volume":"287","author":"Seward","year":"2002","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.vaccine.2021.09.035_b0010","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1001\/jama.294.7.797","article-title":"Impact of varicella vaccination on health care utilization","volume":"294","author":"Zhou","year":"2005","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.vaccine.2021.09.035_b0015","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1056\/NEJMoa042271","article-title":"Decline in mortality due to varicella after implementation of varicella vaccination in the United States","volume":"352","author":"Nguyen","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.09.035_b0020","unstructured":"Immunization, Vaccines and Biologicals, World Health Organization. http:\/\/www.who.int\/immunization\/monitoring_surveillance\/data\/en\/. Accessed Feburary 01, 2021."},{"key":"10.1016\/j.vaccine.2021.09.035_b0025","unstructured":"Vaccine schedules in all countries of the European Union. https:\/\/vaccine-schedule.ecdc.europa.eu\/. Accessed Feburary 01, 2021."},{"issue":"22","key":"10.1016\/j.vaccine.2021.09.035_b0030","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1056\/NEJM198405313102201","article-title":"Live attenuated varicella virus vaccine. Efficacy trial in healthy children","volume":"310","author":"Weibel","year":"1984","journal-title":"New Engl J Med"},{"issue":"9","key":"10.1016\/j.vaccine.2021.09.035_b0035","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/0264-410X(91)90189-D","article-title":"Oka\/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies","volume":"9","author":"Kuter","year":"1991","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2021.09.035_b0040","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1542\/peds.87.5.604","article-title":"Varicella vaccine (VARIVAX) in healthy children and adolescents: results from clinical trials, 1987 to 1989","volume":"87","author":"White","year":"1991","journal-title":"Pediatrics"},{"issue":"10","key":"10.1016\/j.vaccine.2021.09.035_b0045","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1097\/00006454-199510000-00011","article-title":"Over five-year follow-up of Oka\/Merck varicella vaccine recipients in 465 infants and adolescents","volume":"14","author":"Clements","year":"1995","journal-title":"Pediatr Infect Dis J"},{"issue":"11","key":"10.1016\/j.vaccine.2021.09.035_b0050","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/0264-410X(95)00046-4","article-title":"Safety, tolerability, and immunogenicity of two regimens of Oka\/Merck varicella vaccine (Varivax) in healthy adolescents and adults. Oka\/Merck Varicella Vaccine Study Group","volume":"13","author":"Kuter","year":"1995","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2021.09.035_b0055","first-page":"1295","article-title":"Immunogenicity and safety of a live attenuated varicella vaccine in healthy Indian children aged 9\u201324 months","volume":"85","author":"Ramkissoon","year":"1995","journal-title":"South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde"},{"issue":"1","key":"10.1016\/j.vaccine.2021.09.035_b0060","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00006454-199601000-00011","article-title":"Safety and immunogenicity of one vs. two injections of Oka\/Merck varicella vaccine in healthy children","volume":"15","author":"Ngai","year":"1996","journal-title":"Pediatr Infect Dis J"},{"issue":"Supplement 3","key":"10.1016\/j.vaccine.2021.09.035_b0065","doi-asserted-by":"crossref","first-page":"S330","DOI":"10.1093\/infdis\/174.Supplement_3.S330","article-title":"Efficacy of high-titer live attenuated varicella vaccine in healthy young children","volume":"174","author":"Varis","year":"1996","journal-title":"J Infect Dis"},{"issue":"23\u201324","key":"10.1016\/j.vaccine.2021.09.035_b0070","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1016\/S0264-410X(02)00245-1","article-title":"A comparison of safety, tolerability and immunogenicity of Oka\/Merck varicella vaccine and VARILRIX in healthy children","volume":"20","author":"Lau","year":"2002","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2021.09.035_b0075","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1097\/00006454-199912000-00003","article-title":"Postmarketing evaluation of the safety and effectiveness of varicella vaccine","volume":"18","author":"Black","year":"1999","journal-title":"Pediatr Infect Dis J"},{"issue":"7-8","key":"10.1016\/j.vaccine.2021.09.035_b0080","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S0264-410X(00)00297-8","article-title":"The postmarketing safety profile of varicella vaccine","volume":"19","author":"Sharrar","year":"2000","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2021.09.035_b0085","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1001\/jama.284.10.1271","article-title":"Postlicensure safety surveillance for varicella vaccine","volume":"284","author":"Wise","year":"2000","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.vaccine.2021.09.035_b0090","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/01.inf.0000109287.97518.67","article-title":"Ten year follow-up of healthy children who received one or two injections of varicella vaccine","volume":"23","author":"Kuter","year":"2004","journal-title":"Pediatr Infect Dis J"},{"issue":"s2","key":"10.1016\/j.vaccine.2021.09.035_b0095","doi-asserted-by":"crossref","first-page":"S170","DOI":"10.1086\/522161","article-title":"Safety of varicella vaccine after licensure in the United States: experience from reports to the vaccine adverse event reporting system, 1995\u20132005","volume":"197","author":"Chaves","year":"2008","journal-title":"J Infect Dis"},{"issue":"s2","key":"10.1016\/j.vaccine.2021.09.035_b0100","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.1086\/522125","article-title":"The safety profile of varicella vaccine: a 10-year review","volume":"197","author":"Galea","year":"2008","journal-title":"J Infect Dis"},{"issue":"36","key":"10.1016\/j.vaccine.2021.09.035_b0105","doi-asserted-by":"crossref","first-page":"5878","DOI":"10.1016\/j.vaccine.2010.06.056","article-title":"Safety profile of live varicella virus vaccine (Oka\/Merck): five-year results of the European Varicella Zoster Virus Identification Program (EU VZVIP)","volume":"28","author":"Goulleret","year":"2010","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2021.09.035_b0110","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/00006454-200404000-00002","article-title":"Understanding vaccine safety information from the Vaccine Adverse Event Reporting System","volume":"23","author":"Varricchio","year":"2004","journal-title":"Pediatr Infect Dis J"},{"issue":"12","key":"10.1016\/j.vaccine.2021.09.035_b0115","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/pds.1836","article-title":"Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor?","volume":"18","author":"Trifiro","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"10.1016\/j.vaccine.2021.09.035_b0120","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/pds.3197","article-title":"Electronic healthcare databases for active drug safety surveillance: is there enough leverage?","volume":"21","author":"Coloma","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"Supplement 1","key":"10.1016\/j.vaccine.2021.09.035_b0125","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1542\/peds.2010-1722H","article-title":"The Vaccine Safety Datalink: a model for monitoring immunization safety","volume":"127","author":"Baggs","year":"2011","journal-title":"Pediatrics"},{"issue":"Supplement 1","key":"10.1016\/j.vaccine.2021.09.035_b0130","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1542\/peds.2010-1722I","article-title":"Active surveillance for adverse events: the experience of the Vaccine Safety Datalink project","volume":"127","author":"Yih","year":"2011","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.vaccine.2021.09.035_b0135","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/1541-0420.00039","article-title":"A tree-based scan statistic for database disease surveillance","volume":"59","author":"Kulldorff","year":"2003","journal-title":"Biometrics"},{"issue":"5","key":"10.1016\/j.vaccine.2021.09.035_b0140","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/pds.3423","article-title":"Drug safety data mining with a tree-based scan statistic","volume":"22","author":"Kulldorff","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2021.09.035_b0145","article-title":"TreeScanTM: A novel data-mining tool for medical product safety surveillance","author":"Kulldorff","year":"2017","journal-title":"International Conference on Pharmacoepidemiology & Therapeutic Risk Management"},{"issue":"4","key":"10.1016\/j.vaccine.2021.09.035_b0150","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/pds.4397","article-title":"Meningococcal conjugate vaccine safety surveillance in the Vaccine Safety Datalink using a tree-temporal scan data mining method","volume":"27","author":"Li","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"10.1016\/j.vaccine.2021.09.035_b0155","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1093\/aje\/kwy023","article-title":"Assessment of Quadrivalent Human Papillomavirus Vaccine Safety Using the Self-Controlled Tree-Temporal Scan Statistic Signal-Detection Method in the Sentinel System","volume":"187","author":"Yih","year":"2018","journal-title":"Am J Epidemiol"},{"issue":"7","key":"10.1016\/j.vaccine.2021.09.035_b0160","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1093\/aje\/kwz104","article-title":"Using the Self-Controlled Tree-Temporal Scan Statistic to Assess the Safety of Live Attenuated Herpes Zoster Vaccine","volume":"188","author":"Yih","year":"2019","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2021.09.035_b0165","unstructured":"Taiwan Centers for Disease Control. https:\/\/www.cdc.gov.tw\/rwd\/professional. Accessed Feburary 01, 2021."},{"key":"10.1016\/j.vaccine.2021.09.035_b0170","unstructured":"The National Health Research Institutes https:\/\/nhird.nhri.org.tw\/en\/index.html. Accessed Feburary 01, 2021."},{"issue":"3","key":"10.1016\/j.vaccine.2021.09.035_b0175","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/INF.0b013e3181f63cf9","article-title":"Herpes zoster and meningitis due to reactivation of varicella vaccine virus in an immunocompetent child","volume":"30","author":"Han","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2021.09.035_b0180","unstructured":"Kulldorff M., TreeScan User Guide. http:\/\/www.treescan.org\/. Accessed Feburary 01, 2021."},{"issue":"3","key":"10.1016\/j.vaccine.2021.09.035_b0185","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1542\/peds.88.3.604","article-title":"Immunogenicity of subcutaneous versus intramuscular Oka\/Merck varicella vaccination in healthy children","volume":"88","author":"Dennehy","year":"1991","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.vaccine.2021.09.035_b0190","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1017\/S0950268811001786","article-title":"The incidence of varicella and herpes zoster in Taiwan during a period of increasing varicella vaccine coverage, 2000\u20132008","volume":"140","author":"Chao","year":"2012","journal-title":"Epidemiol Infect"},{"issue":"Rr-4","key":"10.1016\/j.vaccine.2021.09.035_b0195","first-page":"1","article-title":"Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"56","author":"Marin","year":"2007","journal-title":"MMWR Recomm Rep"},{"issue":"44","key":"10.1016\/j.vaccine.2021.09.035_b0200","doi-asserted-by":"crossref","first-page":"e1721","DOI":"10.1097\/MD.0000000000001721","article-title":"Combination Measles-Mumps-Rubella-Varicella Vaccine in Healthy Children: A Systematic Review and Meta-analysis of Immunogenicity and Safety","volume":"94","author":"Ma","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.vaccine.2021.09.035_b0205","first-page":"CD004407","article-title":"Vaccines for measles, mumps, rubella, and varicella in children","volume":"4","author":"Di Pietrantonj","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"10.1016\/j.vaccine.2021.09.035_b0215","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1016\/j.vaccine.2020.01.090","article-title":"Assessment of pre-specified adverse events following varicella vaccine: A population-based self-controlled risk interval study","volume":"38","author":"Liu","year":"2020","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2021.09.035_b0220","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/aje\/kwab022","article-title":"A Broad Safety Assessment of the 9-Valent Human Papillomavirus Vaccine","volume":"190","author":"Yih","year":"2021","journal-title":"Am J Epidemiol"},{"issue":"21","key":"10.1016\/j.vaccine.2021.09.035_b0225","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1016\/j.vaccine.2020.04.007","article-title":"Bacillus Calmette-Gu\u00e9rin (BCG) vaccine safety surveillance in the Korea Adverse Event Reporting System using the tree-based scan statistic and conventional disproportionality-based algorithms","volume":"38","author":"Kim","year":"2020","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21012263?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21012263?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T08:17:34Z","timestamp":1777537054000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21012263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":44,"journal-issue":{"issue":"43","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0264410X21012263"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.09.035","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety surveillance of varicella vaccine using tree-temporal scan analysis","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.09.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}